EICHOR
● Active Not Recruiting
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
Condition: Advanced Malignant Solid Neoplasm · Metastatic Malignant Solid Neoplasm · Unresectable Malignant Solid Neoplasm · Sponsor: National Cancer Institute (NCI)
About this study
This phase Ib trial seeks to identify the side effects and best dose of the combination of copanlisib and olaparib when given together with durvalumab. The trial will evaluate how well the drug combinations work in treating patients with advanced cancers who have solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves and may stop growing. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The treatment combinations of copanlisib and olaparib or copanlisib, olaparib, and durvalumab may work better in treating patients with solid tumors compared to usual treatments such as surgery, radiation, or other chemotherapy drugs.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (17)
| Keck Medicine of USC Buena Park | Buena Park, California, United States | — |
| Keck Medicine of USC Koreatown | Los Angeles, California, United States | — |
| Los Angeles General Medical Center | Los Angeles, California, United States | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| USC Norris Oncology/Hematology-Newport Beach | Newport Beach, California, United States | — |
| Keck Medical Center of USC Pasadena | Pasadena, California, United States | — |
| UCHealth University of Colorado Hospital | Aurora, Colorado, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
+ 5 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.